| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IL-17 receptor; IL-17RA; IL17RA; interleukin-17 receptor;;IL 17 receptor A |
| WB Predicted band size | Calculated MW: 96 kDa ; Observed MW: 160 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human IL 17 receptor A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于IL-17A受体抗体的参考文献及其摘要概述：
---
1. **文献名称**：*Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis*
**作者**：Lebwohl MG, et al.
**摘要**：该III期临床试验评估了抗IL-17RA抗体Brodalumab治疗中重度银屑病的效果，结果显示其显著改善皮损症状和患者生活质量，证实靶向IL-17受体通路的有效性。
---
2. **文献名称**：*Interleukin-17 receptor signaling in inflammatory skin pathogenesis*
**作者**：Johansen C, et al.
**摘要**：本文综述了IL-17受体信号在银屑病等炎症性皮肤病中的作用机制，强调阻断IL-17RA可抑制下游促炎因子释放，为治疗提供理论依据。
---
3. **文献名称**：*Anti-IL-17 receptor antibodies enhance Th17 cell migration in autoimmune encephalomyelitis*
**作者**：Kebir H, et al.
**摘要**：研究通过实验性自身免疫性脑脊髓炎(EAE)模型，发现抑制IL-17RA可减少Th17细胞向中枢神经系统的迁移，揭示其在多发性硬化等疾病中的治疗潜力。
---
4. **文献名称**：*Targeting the IL-17 receptor axis in rheumatoid arthritis*
**作者**：Genovese MC, et al.
**摘要**：该研究探讨了抗IL-17RA抗体在类风湿关节炎(RA)中的疗效，结果显示其可缓解关节炎症和骨侵蚀，但疗效受患者亚群异质性影响。
---
这些文献涵盖临床研究、机制综述及疾病模型应用，反映了IL-17受体抗体在免疫疾病中的关键作用。
The IL-17A receptor (IL-17RA) is a key component of the IL-17 signaling pathway, which plays a central role in mediating inflammatory and autoimmune responses. As a type I transmembrane protein, IL-17RA pairs with IL-17RC to form a functional receptor complex that binds IL-17A and IL-17F cytokines. Upon activation, it triggers downstream pro-inflammatory pathways, including NF-κB and MAPK, driving the production of cytokines, chemokines, and antimicrobial peptides. Dysregulation of IL-17 signaling is implicated in chronic inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
IL-17RA-targeted antibodies, such as brodalumab, are biologic therapies designed to block IL-17-mediated signaling by binding to the receptor and preventing cytokine-receptor interaction. This inhibition reduces inflammatory cascades, offering therapeutic benefits in IL-17-driven conditions. Brodalumab, a fully human monoclonal antibody, has demonstrated efficacy in phase III trials for moderate-to-severe plaque psoriasis, showing rapid and sustained skin clearance. However, targeting IL-17RA may carry risks, including increased susceptibility to infections like mucocutaneous candidiasis, reflecting the receptor's role in mucosal immunity.
Research continues to explore IL-17RA antibodies in broader autoimmune indications, with ongoing studies assessing their potential in diseases like asthma and inflammatory bowel disease. These therapies represent a precision medicine approach to modulating hyperactive immune pathways while balancing efficacy and safety profiles.
×
